The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

Notwithstanding its achievements, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) still faces difficulties in the anti-VEGF market, as EYLEA sales are being impacted by growing biosimilar competition.

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

but that was offset by higher rates of inflammatory reactions in the eyes – some of which could be sight threatening – compared to rival anti-VEGF therapy Eylea (aflibercept) from Bayer and ...

The study enrolled 52 DME patients with poor vision despite prior anti-VEGF treatment and was randomized equally to receive either 10 μg UBX1325 or 2 mg of REGN’s Eylea. UBX1325 is UNITY ...